Enanta Pharmaceuticals, Inc. — Form 10-Q Summary
Business context and period: Biotechnology company focused on small-molecule therapies for viral infections and liver diseases. This report covers the three and six months ended March 31, 2019 (fiscal Q2 and first half of fiscal 2019); dollar amounts below are in millions unless stated otherwise. Revenue was derived from royalties under the AbbVie HCV collaboration. Enanta reported no remaining milestones available under that agreement.
Financial results and liquidity
| Metric | Three months ended March 31, 2019 | Six months ended March 31, 2019 |
|---|---|---|
| Revenue | $39.6 | $109.5 |
| Operating expenses | $40.9 | $83.0 |
| Operating income (loss) | $(1.3) | $26.6 |
| Net income | $4.1 | $30.2 |
| Diluted earnings per share | $0.20 | $1.44 |
- Quarterly operating margin was approximately negative 3.3%; first-half operating margin was approximately 24.2%. Quarterly net income included a $3.2 million tax benefit despite pretax income of $0.9 million.
- First-half operating cash flow was $60.3 million, versus cash used of $3.2 million in the prior-year period. Investing activities used $19.6 million and financing activities provided $1.4 million; cash, cash equivalents and restricted cash increased $42.1 million.
- At March 31, cash and cash equivalents were $106.0 million; short- and long-term marketable securities totaled $280.6 million. Management reported $386.7 million of cash, cash equivalents and marketable securities available as principal liquidity resources. Current assets were $423.8 million and current liabilities $20.5 million.
- No debt was outstanding other than a capital lease obligation; the obligation was $0.25 million. Series 1 nonconvertible preferred stock, carried as a liability, was $1.6 million.
Material changes versus comparable periods
- Second-quarter revenue fell about 10% from $44.0 million, entirely due to lower royalties. Enanta attributed the decline to lower international HCV sales; royalties also begin each calendar year at the lowest tier.
- Second-quarter R&D expense rose about 59% to $34.2 million, and total operating expenses increased about 51% to $40.9 million. The increase reflected advancing clinical and preclinical programs, external development costs and higher headcount. Net income fell from $12.6 million to $4.1 million.
- First-half revenue increased about 33% from $82.2 million, while royalties rose to $109.5 million from $67.2 million. The prior-year period included a $15.0 million milestone that did not recur; thus, the total-revenue increase understates royalty growth.
- First-half R&D expense increased about 75% to $69.0 million. First-half net income increased from $24.2 million to $30.2 million, supported by higher royalties and lower income-tax expense.
- At March 31, 2019, total assets were $461.6 million and stockholders’ equity was $436.2 million, compared with $414.2 million and $393.7 million, respectively, at September 30, 2018.
Outlook, management commentary and risks
- Management expected fiscal 2019 revenue to come from AbbVie royalties and said existing financial resources and continuing royalties should fund operations for the foreseeable future. It cautioned that future HCV sales and development costs are uncertain and that profitability is not assured.
- AbbVie’s cited full-calendar-year 2019 HCV sales guidance was $3.3 billion, compared with reported 2018 HCV sales of $3.6 billion. Enanta’s royalties depend on AbbVie’s sales, pricing, market share, reimbursement and applicable royalty tiers.
- R&D spending was expected to continue increasing as programs advance. Enanta reported completing enrollment in the EDP-938 RSV Phase 2a challenge study, with top-line results expected mid-calendar 2019; completing enrollment in the EDP-305 NASH ARGON-1 Phase 2 study, with top-line data expected by the end of calendar Q3 2019; ongoing enrollment in the EDP-305 PBC INTREPID study, expected to continue into 2020; and plans to begin an EDP-514 HBV Phase 1 study in calendar Q3 2019.
- Key risks include dependence on AbbVie and a concentrated HCV royalty stream; potential HCV pricing, competition and reimbursement pressure; clinical, safety, regulatory and funding risks for early-stage programs; reliance on third-party manufacturers and clinical research organizations, including suppliers and research activity in China; and intellectual-property risks. The filing disclosed no current threatened or pending litigation and no material changes in commitments and contingencies during the six-month period.
- Enanta adopted ASC 606 in fiscal 2019 using the modified retrospective method; adoption did not affect its financial statements. Management concluded disclosure controls were effective and reported no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- AbbVie’s subsequent HCV sales, pricing, market share and reimbursement trends, and how those translate into Enanta’s tiered royalties.
- Whether management’s stated trial-result and study-start timelines were met, and the clinical efficacy and safety results for EDP-938 and EDP-305.
- Actual R&D spending and cash use as the pipeline advances, compared with management’s expectation that available resources would support operations for the foreseeable future.
- The drivers and sustainability of quarterly tax benefits and the effective tax rate, including the impact of stock-award deductions and R&D credits.